Lonza, which hopes to make smaller batches of active ingredients for the U.S. biotechnology company’s experimental vaccine by July, now aims to finish a commercial production line in Portsmouth, New Hampshire, a month or so earlier than its original December 2020 target, Albert Baehny told Reuters. A second commercial line, at Lonza’s site in Visp, Switzerland, had been slated for completion in January or February 2021 but now could be ready in December, he added. Source: Reuters 2/6/2020